An EORTC phase II study of methyl-glyoxal bis-guanylhydrazone in advanced renal cell cancer.

Abstract

In a phase II study of methyl-glyoxal bis-guanylhydrazone (methyl-GAG) in patients with bi-dimensionally measurable metastases of renal cell cancer, 30 patients were given 500 mg/m2 weekly for at least 4 treatment cycles and were evaluable for response. Three patients (10%) achieved partial remission (PR) with a duration of 8-12 weeks; in 11 patients the disease was assessed as stable; and in 16 there was progression. A total of 40 patients were evaluable for toxicity. Nausea and vomiting occurred in 17 (43%), neuropathy, myopathy or myalgia in 8 (21%) and mucositis in 6 (14%). In addition to 3 patients taken off treatment before 4 treatment cycles, toxicity precluded further treatment in 3 others after 5, 6 and 7 cycles respectively. Methyl-GAG has minimal activity in renal cell cancer and, in this dose schedule, causes appreciable toxicity.

• Authors: J A Child, A V Bono, S D Fossa, W W Ten Bokkel Huinink, M De Pauw, G Stoter
• Journal: European journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 18 Issue 1 Pg. 85-7 (Jan 1982) ISSN: 0277-5379 [Print] England
• PMID: 7200896 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Guanidines
• Mitoguazone

Topics

• Adenocarcinoma (drug therapy)
• Adult
• Aged
• Antineoplastic Agents (administration & dosage, adverse effects)
• Digestive System (drug effects)
• Drug Evaluation
• Guanidines (administration & dosage)
• Humans
• Kidney Neoplasms (drug therapy)
• Middle Aged
• Mitoguazone (administration & dosage, adverse effects)
• Nervous System (drug effects)